Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JNJ-42756493

Known as: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 
An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, JNJ… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2018
Highly Cited
2018
4503Background: ERDA is an FGFR inhibitor with activity in pts with mUC and FGFRalt. FGFRalt occur in 10-20% of mUC and are… Expand
2018
2018
411Background: Although immune checkpoint inhibitors (ICI) have improved outcomes in some pts with platinum-resistant mUC, many… Expand
Highly Cited
2017
Highly Cited
2017
Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes ranging from embryogenesis to wound… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Fibroblast growth factor receptor (FGFR) genetic alterations are frequently observed in cancer, suggesting that FGFR inhibition… Expand
Highly Cited
2015
Highly Cited
2015
PURPOSE JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. This first… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2015
Highly Cited
2015
Purpose: Oncogenic fusions consisting of fibroblast growth factor receptor (FGFR) and TACC are present in a subgroup of… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
2015
2015
BackgroundWe examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of fibroblast growth… Expand
2014
2014
2501 Background: JNJ-42756493 is an orally bioavailable FGFR 1, 2, 3 and 4 inhibitor with nanomolar antitumor activity in cell… Expand
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: JNJ-42756493 is an FGFR 1, 2, 3, and 4… Expand